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Background: In severe stroke, a decision to withdraw life-sustaining treatment is sometimes 
made in cooperation with the family. The aim of this study was to study the time from  withdrawing 
life-sustaining treatment to death in patients with severe ischemic or hemorrhagic stroke.
Methods: In total, 2,506 patients with stroke admitted to Haukeland University Hospital between 
2006 and 2011 were prospectively registered in the Bergen NORSTROKE database. Risk fac-
tors, stroke severity, etiology, and blood analyses were registered. Retrospectively, the patients’ 
records were examined to determine the number of days from withdrawing all life-sustaining 
treatment to death in patients who died from severe stroke during the hospital stay.
Results: Life-sustaining treatment was withheld in 50 patients with severe stroke. Median time to 
death after withdrawing life-sustaining treatment was 4 days, and a quarter lived at least 1 week 
(range =1–11 days). Cox regression analyses showed that short time from withdrawing life-
sustaining treatment to death was associated with high age (Hazard ratio [HR] =1.05, P=0.07), 
male sex (HR =2.9, P=0.01), high C-reactive protein on admission (HR =1.01, P=0.001), and 
hemorrhagic stroke (versus ischemic stroke, HR =1.5, P=0.03).
Conclusion: One week after withdrawing life-sustaining treatment, a quarter of our patients 
with severe stroke remained alive. Short time to death was associated with high age, male sex, 
hemorrhagic stroke, and high C-reactive protein on admittance.
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Introduction
In-hospital mortality occurs among one-third of the patients with hemorrhagic stroke1,2, 
and in-hospital mortality for ischemic stroke varies from 3% to 9%.2–6 The percentage 
of patients with severe stroke has possibly increased in recent years.7 Factors associated 
with early mortality include stroke severity, age, previous stroke, atrial fibrillation, 
diabetes mellitus, and pneumonia.1,4,6
It is the routine in our department to discuss treatment options thoroughly with 
the patient’s family when the stroke is severe. In some cases, when the prognosis is 
considered to be poor, a joint decision is made to withdraw all life-sustaining  treatments 
including saline and nutrition and only provide alleviating treatment such as morphine 
and diazepam. These patients have persistent reduction of consciousness and are unable 
to eat or drink orally. Reliable evidence is needed when making these decisions, and 
more research on this topic is requested.4
The aim of the present retrospective study was to investigate the number of days 
from withdrawal of life-sustaining treatment to death in patients with severe stroke.






All consecutive patients with acute cerebral infarction and 
cerebral hemorrhage (the index stroke) admitted to the Stroke 
Unit, Department of Neurology, Haukeland  University 
Hospital between February 2006 and February 2011 
were prospectively registered in a database (The Bergen 
 NORSTROKE Registry). Stroke was defined in accordance 
with the World Health Organization’s definition of stroke.8 
Stroke due to trauma or sinus venous thrombosis were 
excluded. All had CT and/or MRI. Exact time of onset of 
stroke, admission, and death were registered. The National 
Institute of Health Stroke Scale (NIHSS) was used to assess 
stroke severity on admission.
Traditional risk factors were registered: angina  pectoris, 
myocardial infarction, intermittent claudication,  hypertension, 
diabetes mellitus, and smoking. Current smoking was defined 
as smoking at least one cigarette per day. Diabetes mellitus 
was considered present if the patient was on glucose-lowering 
diet or medication. Hypertension, angina pectoris, myocardial 
infarction, and peripheral artery disease were considered 
present if diagnosed by a physician any time before the onset 
of stroke. Blood analyses including C-reactive protein (CRP) 
were performed on admission.
For some patients, a decision to withdraw life- sustaining 
treatment is routinely performed after evaluation of  prognosis 
with the family. These patients suffer from severe deficits 
including reduced consciousness and  inability to  communicate. 
The decision was made on weekdays after summoning the 
family to a meeting in the hospital.  Retrospectively, the 
patients’ records (electronic patient journal) were examined by 
one of the authors (EH) to determine the number of days from 
withdrawing all life-sustaining treatment to death because of 
poor prognosis after a written joint  decision with the family. 
Life-sustaining treatment was defined as the provision of 
water and nutrition or antibiotics in case of infection. Patients 
without life-sustaining treatment usually received alleviating 
treatment, which included morphine 2.5 mg subcutaneously 
four times daily or more.
Poor prognosis was not defined, but poor prognosis was 
considered present in patients with stroke with reduced 
consciousness and high probability of dying irrespective of 
treatment due to large cerebral infarction or hemorrhage. 
Patients with poor prognosis were unable to communicate 
and unable to eat and drink orally.
Additional analyses were done including all patients who 
died during the hospital stay. Comparisons were performed 
between patients who died with or without withdrawal of 
life-sustaining treatment.
The study was approved by the local ethics committee, 
REK Vest.
statistics
Student’s t-test, pair-wise correlation, chi-square, and Cox 
regression analyses were used when appropriate. P-value ,0.05 
was considered statistically significant. Analyses were  carried 
out using STATA 13.1 (StataCorp LP, College Station, 
TX, USA).
Results
Patients who died after withdrawing  
life-sustaining treatment
Retrospectively, time for withdrawing life-sustaining treat-
ment was identified in the patient records for 50 patients: 
34 patients with ischemic stroke and 16 patients with hem-
orrhagic stroke. Median NIHSS score on admission was 
27 (inter-quartile range [IQR] =20–30). In comparison, the 
median NIHSS score was 3 (IQR =1–8) among patients who 
were discharged alive. The location was more frequent in the 
anterior than the posterior circulation territory for patients 
with cerebral infarction who died after withdrawing life-
 sustaining treatment compared with surviving patients 
(94% vs 80%, P=0.04). The mean number of days from onset 
of stroke to death was 9.8 days (SD =6.7), the median 8 days 
(IQR =5–14), and the range 2–30 days. The mean number of 
days from withdrawing all life-sustaining treatments to death 
was 4.7 days (SD =2.9), and the range was 1–11 days. Table 1 
shows percentiles for the number of days from  withdrawing 
life-sustaining treatment to death. The mean number of 
days from the onset of stroke to withdrawing life-sustaining 
treatment was 5.0 days (SD =5.7), the median was 3 days 
(IQR =1–8), and the range was 0–26 days.
Figure 1 shows Kaplan–Meier curves for days from with-
drawing life-sustaining treatment to death for patients with 
ischemic stroke and hemorrhagic stroke separately.
Cox regression analyses showed that short time from 
withdrawing life-sustaining treatment to death was  associated 
Table 1 Percentiles and days since withdrawing life-sustaining 
treatment to death in patients with stroke












Withdrawal and non-withdrawal of life-sustaining treatment in acute stroke
with high age (Hazard ratio [HR] =1.05, P=0.07), male sex 
(HR =2.9, P=0.01), high CRP on admission (HR =1.01, 
P=0.001), and hemorrhagic stroke (versus ischemic stroke) 
(HR =1.5, P=0.03). The number of days from withdrawal of 
life-sustaining treatment to death was not associated with 
the number of days from the onset of stroke to withdrawal 
of life-sustaining treatment (HR =0.98, P=0.4).
In total, 43 (86%) patients received morphine as alleviat-
ing treatment after withdrawing life-sustaining treatment.
comparing withdrawal and non-
withdrawal of life-sustaining treatment 
among patients who died
Of 2,506 patients with stroke, 2,217 (88%) had ischemic 
stroke and 289 (12%) had hemorrhagic stroke. Among 
patients with ischemic stroke, 118 (5.3%) died, and among 
patients with hemorrhagic stroke, 66 (23%) died during the 
hospital stay. Among patients who died, withdrawal of 
 life-sustaining treatment was associated with higher age and 
longer time till death (Table 2).
Discussion
The main finding in our study was that the median time from 
withdrawing life-sustaining treatment to death in patients 
with severe stroke was 4 days. Although 4 days is a relatively 
short period, it is important to recognize that about a quarter 
of the patients lived a week or longer. All died within 11 days 
of withdrawing life-sustaining treatment, and the majority 
died within a few days in accordance with the poor prognosis 
of these patients. There was very little doubt among the physi-
cians about the poor prognosis among these patients before 
withdrawing life-sustaining treatment. This knowledge may 
be helpful for family and caretakers in order to cope with 
the period after withdrawing life- sustaining treatment. For 
comparison, only two of 110 patients in an intensive care unit 
lived more than 7 days after withdrawing life-sustaining treat-
ment.9 However, the majority of those patients were weaned 
off positive-pressure ventilation as part of the procedure to 
withdraw life-sustaining treatment.
Our analyses disclosed a number of factors  associated 
with time from withdrawing life-sustaining  treatment to 
death. The time was shorter for older patients, male sex, and 
patients with high CRP on admittance and cerebral hemorrhage. 
Older patients are frailer, and multiple organ failure prob-
ably occurs sooner. High CRP on admittance may signify 
an infection or other underlying disease,  making the patient 
more prone to multiorgan failure and early death. Cerebral 
hemorrhage was also associated with shorter time to death 
after withdrawing life-sustaining treatment than ischemic 
stroke. A possible explanation is that  hemorrhagic stroke 
tends to be more severe than ischemic stroke. However, after 
adjusting for stroke severity assessed by the NIHSS score, 
hemorrhagic stroke was still associated with shorter time to 
death than ischemic stroke.
In-hospital mortality was low for both patients with 
ischemic and hemorrhagic stroke compared with other 
studies.1,6 This indicates that the decision to withdraw life-
sustaining treatment occurred in patients with severe stroke 
and very poor prognosis, and it is unlikely that neurologists 
in our department were overly pessimistic in  prognosticating 
outcome.2
Our study has some limitations. The most important limita-








Cerebral infarction Hemorrhagic stroke
Figure 1 Kaplan–Meier curves showing days from withdrawing life-sustaining 
treatment to death in 50 patients with severe cerebral infarction or hemorrhagic 
stroke (P=0.20).
Table 2 characteristics of patients who died in hospital after 






Male 18 (36) 64 (48) 0.15
Female 32 (64) 70 (52) –
age (sD) 83 (9) 78 (13) 0.03
niHss score on  
admission (sD)
22 (8) 20 (8) 0.09
Days to death (sD) 10 (7) 6 (8) 0.01
ischemic stroke 34 (68) 84 (63) 0.50
Hemorrhagic stroke 16 (32) 50 (37) –
glucose (sD) 7.3 (2.1) 8.5 (3.1) 0.01
Diabetes mellitus 7 (14) 25 (19) 0.45
c-reactive protein 24 (44) 28 (54) 0.68
Hypertension 22 (44) 65 (49) 0.59
Atrial fibrillation 20 (40) 57 (43) 0.76
Abbreviations: niHss, national institute of Health stroke scale; sD, standard 
deviation.
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life-sustaining treatment. However, a  prospective study on 
this topic is in our opinion unethical, because it is possible 
that an ongoing, prospective study might influence on the 
decision of withdrawing life-sustaining treatment or not. 
Data on CT or MRI immediately prior to this decision were 
not available for analyses.
Conclusion
In conclusion, 1 week after withdrawing life-sustaining 
 treatment, a quarter of the patients with severe stroke 
remained alive in our department. Short time to death was 
associated with high age, male sex, hemorrhagic stroke, and 
high CRP on admission.
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